NGeneBio (Seoul, Korea) introduced its next-generation sequencing (NGS)-based oncology/genetic disease kits and NGenePlex nCoV qRT-PCR kit against COVID-19 at AACC 2021.
Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, laboratory management, and other areas of cutting-edge laboratory science.
At AACC 2021, NGeneBio introduced its NGS (BRCA/HEME/SOLID/ONCO/HLA) genetic disease/oncology kits. NGeneBio’s BRCAaccuTest and BRCAaccuTest PLUS are a kit of reagents for producing libraries to analyze BRCA1 and BRCA2 genes using the NGS method, which analyzes genomic DNA derived from blood or FFPE tissue. The kit is designed for patients with breast and ovarian cancer, patients with HBOC (hereditary breast and ovarian cancer syndrome), and for family history or age of breast cancer incidence.
Also on display at the event were NGeneBio’s HEMEaccuTest for molecular genetics testing of multiple genes related to hematologic malignancy; SOLIDaccuTest to explore variants associated with solid tumours using a comprehensive NGS approach; HLAaccuTest All, which is an in vitro diagnostic medical device for HLA (human leukocyte antigen) typing that can identify high-resolution histocompatibility antigens using NGS; and ONCOaccuPanel, a comprehensive NGS test for solid tumour oncology.
In addition, NGeneBio demonstrated its NGeneAnalySys software for analysis of genetic test data produced by NGS and helps inform clinical grade for oncology testing, along with EasyHLAanalyzer that provides HLA typing that identifies human leukocyte antigen to histocompatibility antigens using NGS data. Also on display at AACC 2021 was NGeneBio’s NGenePlex nCoV qRT-PCR Kit, which is a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay reagent intended for the qualitative detection of SARS nucleic acid -CoV-2 from infected patients. or suspected of COVID-19.